Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Enobosarm plus semaglutide

INVESTIGATIONAL

Selective androgen receptor modulation combined with GLP-1 receptor agonism

1
graded results
0
ongoing records
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Enobosarm plus semaglutide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Lean-mass preservation during semaglutide-associated weight loss; Co-administered oral enobosarm and subcutaneous semaglutide; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Enobosarm plus semaglutide INVESTIGATIONAL
body-composition Mixed
Very low evidence

Veru's phase 2b QUALITY trial (NCT06282458) tested enobosarm added to semaglutide in adults aged 60 years or older. Sponsor-issued topline results reported less...

Veru Inc., Phase-2b QUALITY topline press release, 27 Jan 2025; NCT06282458 Source
Full findingVeru's phase 2b QUALITY trial (NCT06282458) tested enobosarm added to semaglutide in adults aged 60 years or older. Sponsor-issued topline results reported less lean-mass loss and a stair-climb-power responder signal than with placebo plus semaglutide. No peer-reviewed publication of these efficacy results was identified at the catalogue date.
PopulationQUALITY phase-2b dose-finding RCT, N=168, double-blind placebo-controlled, 16 weeks, adults >=60 y on semaglutide; enobosarm 3/6 mg vs placebo.
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Comparatorsplacebo + semaglutide